5Dickstein K, Larsen A I, Bonarjee V. Plasma Proatrial Natriuretic Factor is Predictive of Clinical Status in Patients with Congestive Heart Failure. Am J Cardiol, 1995,766(10) :679.
6Willette R N, Anderson K M, Nelson A H, et al. Enrasentan Improves Survival, Limits Left Ventricular Remodeling, and Preserves Myocardial Performance in Hypertensive Cardiac Hypertrophy and Dysfunction. J Cardiovasc Pharmacol, 2001, 38(4) :606.
7Foster K A, Hock C E, Rwibel D K. Altered Responsiveness of Hypertrophied Rat Hearts to Alpha-and Beta-adrenergic Stimulation. J Med Cell Cardiol ,1991, 23: 91.
8Michner M L, Gierse J K, Seetharam R, et al. Proteolytic Processing of Atriopeptin Prohormone. Mol Pharmaool, 1986, 30:552.
9Jngdutl B I, Amy R W M. Healing after Myocardial Infarction in the Dog : Changes in Infarct Hydroxyproline and Topography.JACC, 1986, 7(1): 91.
10Vesely D L, Douglass M A, Dietz J R, et al. Three Peptides from the Atrial Natriuretic Factor Prohormone Amino Terminus Lower Blood Pressure and Produce Diuresis, Natriuresis, and/or Kaliuresis in Humans. Circulation, 1994, 90(3): 1129.
